JPMorgan Chase & Co. Has $99.68 Million Holdings in Waters Corporation $WAT

JPMorgan Chase & Co. boosted its holdings in shares of Waters Corporation (NYSE:WAT) by 54.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 332,447 shares of the medical instruments supplier’s stock after acquiring an additional 117,098 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.56% of Waters worth $99,675,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in WAT. Root Financial Partners LLC acquired a new stake in shares of Waters in the third quarter worth about $26,000. ANTIPODES PARTNERS Ltd bought a new stake in Waters during the third quarter worth approximately $26,000. Hantz Financial Services Inc. grew its holdings in Waters by 115.4% during the third quarter. Hantz Financial Services Inc. now owns 112 shares of the medical instruments supplier’s stock valued at $34,000 after purchasing an additional 60 shares during the last quarter. CYBER HORNET ETFs LLC bought a new position in shares of Waters in the second quarter valued at approximately $53,000. Finally, Versant Capital Management Inc lifted its stake in shares of Waters by 510.3% in the third quarter. Versant Capital Management Inc now owns 177 shares of the medical instruments supplier’s stock worth $53,000 after buying an additional 148 shares during the last quarter. 94.01% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on WAT. Citigroup started coverage on shares of Waters in a report on Tuesday, February 10th. They set a “buy” rating and a $425.00 price objective for the company. Robert W. Baird set a $363.00 target price on shares of Waters in a research report on Tuesday, February 10th. HSBC started coverage on shares of Waters in a report on Tuesday, January 27th. They set a “buy” rating and a $460.00 price target for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Waters in a research note on Wednesday, January 21st. Finally, UBS Group lowered their target price on Waters from $395.00 to $370.00 and set a “neutral” rating on the stock in a report on Tuesday, February 10th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Waters currently has an average rating of “Moderate Buy” and an average price target of $393.84.

Waters Stock Up 2.4%

NYSE WAT opened at $297.09 on Wednesday. Waters Corporation has a 1-year low of $275.05 and a 1-year high of $414.15. The company has a current ratio of 1.73, a quick ratio of 1.27 and a debt-to-equity ratio of 0.37. The stock’s 50 day moving average is $348.50 and its two-hundred day moving average is $351.50. The company has a market capitalization of $29.14 billion, a price-to-earnings ratio of 27.59, a PEG ratio of 2.00 and a beta of 1.20.

Waters (NYSE:WAT) last posted its earnings results on Monday, February 9th. The medical instruments supplier reported $4.53 EPS for the quarter, topping the consensus estimate of $4.50 by $0.03. Waters had a return on equity of 34.79% and a net margin of 20.30%.The business had revenue of $932.36 million during the quarter, compared to the consensus estimate of $928.17 million. During the same quarter last year, the company earned $4.10 EPS. Waters’s revenue was up 6.9% on a year-over-year basis. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. Equities analysts forecast that Waters Corporation will post 12.86 earnings per share for the current fiscal year.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.